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Abstract
Objective: To field test a standardized instrument to measure nonsevere morbidity 
among antenatal and postpartum women.
Methods: A cross- sectional study was conducted in Jamaica, Kenya, and Malawi 
(2015–2016). Women presenting for antenatal care (ANC) or postpartum care (PPC) 
were recruited if they were at least 28 weeks into pregnancy or 6 weeks after delivery. 
They were interviewed and examined by a doctor, midwife, or nurse. Data were col-
lected and securely stored electronically on a WHO server. Diagnosed conditions 
were coded and summarized using ICD- MM.
Results: A total of 1490 women (750 ANC; 740 PPC) averaging 26 years of age par-
ticipated. Most women (61.6% ANC, 79.1% PPC) were healthy (no diagnosed medical 
or obstetric conditions). Among ANC women with clinical diagnoses, 18.3% had direct 
(obstetric) conditions and 18.0% indirect (medical) problems. Prevalences among PPC 
women were lower (12.7% and 8.6%, respectively). When screening for factors in the 
expanded morbidity definition, 12.8% (ANC) and 11.0% (PPC) self- reported exposure 
to violence.
Conclusion: Nonsevere conditions are distinct from the leading causes of maternal 
death and may vary across pregnancy and the puerperium. This effort to identify and 
measure nonsevere morbidity promotes a comprehensive understanding of morbidity, 
incorporating maternal self- reporting of exposure to violence, and mental health. 
Further validation is needed.
K E Y W O R D S
Antenatal care; Interpersonal violence; Maternal morbidity; Measurement; Nonsevere maternal 
morbidity; Postpartum care; Pregnancy and puerperium
1  | INTRODUCTION
As global attention shifts from surviving pregnancy and child-
birth to ensuring that women thrive throughout their lives, much 
remains to be done to ensure that women have a positive preg-
nancy experience, and to lessen the risks of pregnancy and child-
birth that can lead to harmful consequences. Within the construct 
of Sustainable Development Goal (SDG) target 3.1 within SDG 3, 
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and the Global Strategy to End Preventable Maternal Mortality 
(EPMM),1,2 improving the measurement of maternal health will be 
key. Building on the success of the WHO in defining and measuring 
maternal near- miss events,3 which also established parameters for 
quality of care for severe maternal complications/morbidities, action 
is now focused on standardizing and measuring non- life- threatening 
maternal morbidity.
As maternal mortality trends downward, measuring morbidity will 
be critical to monitoring the quality of maternal health care. Based 
on previous efforts of the WHO Department of Reproductive Health 
and Research (RHR) to standardize the measurement and report-
ing of maternal mortality and severe maternal morbidity, efforts 
are  expanding to also address measurement of non- life- threatening 
(nonsevere) maternal morbidity, especially given that the often- cited 
maternal morbidity estimate of around 20–30 morbidities for every 
maternal death is “not based on standard, well documented, and trans-
parent methodologies”.4
RHR implemented a 5- year project to address the lack of a scien-
tific basis for defining, estimating, and monitoring the magnitude of 
maternal morbidity. It was envisioned that in addition to standardiz-
ing what is called maternal morbidity and how it is measured, doing 
so would not only assist program managers and policy makers to bet-
ter monitor maternal morbidity, but it would also bring attention and 
resources to enhancing care for pregnant and postpartum women. The 
present paper describes the initial performance of this new set of stan-
dardized maternal morbidity measurement tools, and represents the 
final step in a larger initiative (described in the methods section) that 
seeks to advocate for and improve women’s health.
The pilot study sought to field test a comprehensive instrument to 
measure nonsevere morbidity among women in antenatal care (ANC) 
and postpartum care (PPC). The paper presents study findings and 
insights into its future use. Subobjectives included:
1. Describing the sociodemographic characteristics of the women 
recruited, by country.
2. Examining the contributory factors and clinical indicators identified 
and their relationship to obstetric and medical diagnoses among 
pregnant and postpartum women.
3. Exploring the feasibility and challenges associated with administer-
ing the instrument (for research purposes only).
2  | MATERIALS AND METHODS
This study is the culmination of a 5- year initiative led by the Maternal 
Morbidity Working Group (MMWG) convened by RHR, the details of 
which have been published elsewhere.4–6 In brief, the group, com-
posed of technical experts in maternal and women’s health, began 
by defining non- life- threatening (hereafter referred to as nonsevere) 
maternal morbidities as: “Any health condition attributed to and/or 
complicating pregnancy and childbirth that has a negative impact on 
the woman’s wellbeing and/or functioning”.4
To operationalize this definition, a maternal morbidity matrix 
was developed.4 It outlined three dimensions: (1) WHO’s concep-
tual framework for the application of the International Statistical 
Classification of Diseases and Related Health Problems 10th Revision 
(ICD- 10) to deaths during pregnancy, childbirth, and the puerperium 
(ICD- Maternal Mortality [ICD- MM])7; (2) measurement of functional 
impact and disability8; and (3) evaluation of maternal physical and 
mental health, and social history.
For this pilot, the aforementioned matrix was translated into two 
comprehensive questionnaires: the ANC and PPC maternal morbidity 
measurement instruments. The tools sought a holistic view of mater-
nal health, guided by women’s perspectives. Previously validated 
scales were incorporated, where available, to measure mental health 
(General Anxiety Disorder, 7 item (GAD- 7),9 and the Personal Health 
Questionnaire, 9 item (PHQ- 9)10); health- related functioning, or the 
ability to carry out daily tasks and social responsibilities (using the WHO 
Disability Assessment Schedule (WHODAS 2.0) 12- item version11); sex-
ual satisfaction12; substance use/abuse13; and exposure to violence.14
Both instruments were hour- long questionnaires consisting of 
a patient interview, physical examination, and record review.15 The 
interview documented socioeconomic status, medical and obstetric 
history, and clinical symptoms. The physical examination, conducted 
by a healthcare professional, evaluated clinical signs. The record 
review extracted information on selected laboratory tests and results.
To field test the instruments, a cross- sectional study was con-
ducted in three countries (Jamaica, Kenya, and Malawi) in late 2015 
to early 2016, over 3- month periods in each country. All sites (n=13) 
were public facilities: nine in Jamaica (6 health centers and 3 referral 
hospitals), three in Kenya (2 district and 1 referral hospital), and one in 
Malawi (referral hospital). Efforts were made to include a range of facil-
ities (primary, secondary, and tertiary referral facilities; in urban and 
rural settings) from different subnational areas, although the choice 
also depended on availability of the relevant resources to ensure high- 
quality data collection. Ethical approval was obtained from the WHO 
Ethical Review Committee and relevant entities in each country. To 
describe the different types of morbidity, and enable stratification 
by country setting and time of administration, a sample size of 500 
women per country (250 each, ANC and PPC) was calculated to be 
adequate. Without pooling data across sites or populations, we esti-
mated a 6% margin of error.
Participants were conveniently selected from among women pre-
senting for routine ANC or PPC services. Inclusion criteria were that 
ANC women were at least 28 weeks pregnant, and PPC women were 
6–12 weeks after delivery.15 Women whose pregnancies ended in 
abortion or miscarriage were excluded, while those who experienced 
stillbirths were included. Women provided written informed consent 
before being interviewed.
Health professionals (nurses, midwives, or doctors, depending 
on the site) participated in a 2- day training session to administer 
the ANC and PPC instruments. They were informed about the study 
objectives, introduced to the instruments, learned how to use the 
digital tablets, and gained practical experience before final selec-
tion. A manual detailing standard operating procedures for each 
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question was developed and modified for each country. In Jamaica 
and Kenya, the interviewers were facility staff recruited for this proj-
ect. In Malawi, ANC nurse midwives conducted the physical exam, 
while recent medical graduates were hired specifically to conduct the 
interview portion of the tool.
The instruments were developed in digital format and translated 
into local languages at each site. Data were gathered on tablets 
using OpenDataKit (University of Washington, USA) open- source 
software. The digital tool limited the prevalence of missing values 
as interviewers could not advance until an answer was inputted. For 
women presenting with a condition that warranted referral (mental 
health score, report of violence, need for further testing, or for proce-
dures for a certain condition), interviewers were provided with refer-
ral information on their tablets (such as the department to contact). 
Data were stored and managed on a secure, password- protected, 
cloud- based server system owned by WHO. Research coordinators 
reviewed and approved the submitted electronic records for com-
pleteness and quality.
Conditions diagnosed by the health team were recorded as 
open- ended questions, then coded by a clinical officer (KB), and 
summarized using ICD- 10 and ICD- MM guidelines. Obstetric 
(direct) complications were grouped, using ICD- MM categories, into: 
hypertensive disorders, obstetric hemorrhage, pregnancy- related 
infection, and other specific direct conditions. Indirect (medical) 
conditions were classified by organ system, namely cardiovascu-
lar, hematologic, endocrine, and other medical conditions. Injuries 
(unintentional or otherwise) were classified separately. Contributory 
factors considered included obesity (body mass index ≥30), and self- 
reported experiences such as exposure to violence, anxiety (GAD- 7 
score ≥10), and depression (PHQ- 9 score ≥10). To document prev-
alence of medical conditions, the healthcare provider’s diagnoses 
at the time of interview were the gold standard; however, mental 
health diagnoses were based on results in the standardized GAD 
(anxiety) and PHQ (depression) questionnaires.
To demonstrate the utility of the tool for research and future 
health- service intervention, multivariate (logistic regression) analy-
ses were undertaken. Covariate variables were examined by the fol-
lowing groupings.
1. Contributory factors: substance use, not having a partner, being 
obese, and being sexually dissatisfied.
2. Equity/access: receiving care at a primary or referral facility, urban 
residence, and having only primary level education.
3. Demographic characteristics: age (≥35 years, or ≤20 years), and 
parity (primiparous vs multiparous).
Data were compared among countries using the χ2 test, Fisher 
exact test, or Kruskal- Wallis test, as appropriate. Forward and back-
ward regressions were employed based on P≤0.10. Statistical signifi-
cance was considered to be P≤0.5. Confidence intervals for continuous 
data were based on normal distribution approximation. Statistical 
analyses were conducted in Stata/SE version 14.1 (StataCorp LLC, 
College Station, TX, USA).
3  | RESULTS
Interviews were conducted with 1490 women (750 ANC; 740 PPC). 
Sixteen ANC and 39 PPC women declined to participate. While simi-
lar to the study population, ANC refusers were older (27.6 ± 8.4 vs 
26.2 ± 5.9 years, P<0.001) and PPC refusers were more likely to have 
a partner (86.8% vs 69.3%, P<0.001).
Both the ANC and PPC study populations averaged 26 years 
of age (Tables 1 and 2). Fewer African women were having their 
first child (range, 27.7%–38.8% in both groups) compared with 
Jamaicans (almost 44% in both groups). Only six (0.8%) PPC women 
interviewed reported stillbirths. In Kenya (79.5% ANC; 82.2% PPC) 
and Malawi (92.5% ANC; 89.3% PPC), most women reported hav-
ing a partner, while in Jamaica only 41.9% of ANC and 38.3% of 
PPC women reported having a partner. Jamaican women were also 
least likely to be illiterate (0.8% ANC; 2.0% PPC). While most ANC 
women were employed (52.4%), this declined to 48.1% among PPC 
women. Most participants (85.1% ANC, P<0.001, and 72.8% PPC, 
P<0.001) were recruited from referral sites to ensure that the instru-
ment could be tested on women with a morbid condition in preg-
nancy and the puerperium.
In expanding the definition of morbidity, selected contributory 
factors were explored. We examined exposure to violence by asking 
women whether they had been “afraid of your current/most recent 
husband or partner or anyone else,” or whether “since pregnancy/
delivery, was there ever a time when you were pushed, slapped, hit, 
kicked or beaten by (any of) your husband/partner(s) or anyone else?” If 
women replied affirmatively to either question, they were asked three 
additional violence- related questions. Thirteen percent (12.8%; n=96, 
P=0.018) of ANC and 11.0% (n=81, P<0.001) of PPC women reported 
being afraid of, or having experienced some form of physical violence 
from, their current partner or someone else, with rates varying by 
site from 7% to 17%. We also explored substance use through self- 
reporting (3%–4% overall; Table 3) and, given the global prevalence 
of obesity, women’s heights and weights were documented (Table 4).
Most ANC (61.6%, P=0.018) and PPC (79.1%, P=0.027) women 
were healthy (i.e. they were not diagnosed with any conditions by 
healthcare providers, and did not self- report mental health prob-
lems). Twenty- seven percent (27.3%, n=205) of ANC and 15.1% 
(n=112) of the PPC population were diagnosed with one morbidity 
(including screening positive for depression or anxiety), and 11.1% 
(n=83) of ANC and 5.7% (n=43) of PPC women had two or more 
conditions (Table 5). ANC women were almost equally diagnosed 
with direct (18.3%, n=137, P<0.001) or indirect conditions (18.0%, 
n=135, P<0.001), whereas PPC women were more likely to be diag-
nosed with indirect (12.7%, P<0.001) than with direct conditions 
(8.7%, P=0.036).
Using ICD- MM direct condition groups, ANC women commonly 
presented with pregnancy- related infections (10.4%, n=78, P<0.001), 
hypertensive disorders (2.9%, n=22, P=0.002), and fetal growth/
length anomalies (1.6%, n=12, P=0.581). The hypertensive disorders 
category combines pre- eclampsia, gestational hypertension, and clini-
cal observations of “elevated blood pressure”. The most prevalent PPC 
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direct conditions were hypertensive disorders (4.1%, n=30, P=0.43) 
and pregnancy- related infections (3.8%, n=28, P=0.024). For both 
ANC and PPC women, the most common indirect conditions were 
sexually transmitted infections, vaginitis (6.8%, n=51, P=0.657; 6.5%, 
n=48, P<0.001), and psychiatric conditions (6.4%, n=48, P<0.001; 
2.2%, n=16, P<0.001). Clinical examination documented four women 
with depression in the ANC population, and two women in the PPC 
population (no women were diagnosed with anxiety by a healthcare 
provider). Conversely, the GAD and PHQ found that 6.3% (n=47) of 
ANC and 2.2% (n=16) of PPC women had one or both signs of sig-
nificant distress (Table 5). The psychiatric conditions category there-
fore incorporated diagnosis by a healthcare provider, or scoring 10 or 
above on the GAD- 7 or PHQ- 9 questionnaires.
We conducted univariate and logistical analyses for ANC and PPC 
women to evaluate the associations of contributory and demographic 
factors, if any, with diagnosis of any morbidity (including self- reported 
mental health conditions). The univariate analysis showed that for ANC 
women, substance use (P=0.023), obesity (P=0.008), being sexually 
dissatisfied (P=0.001) or being under 20 years of age (P=0.056) were 
associated with a morbidity diagnosis of any kind. For PPC women, not 
having a partner (P=0.054), rural residence (P=0.043), and being sexu-
ally dissatisfied (P<0.001) were associated with a morbidity diagnosis.
When all factors were included in a backward regression, only sex-
ual dissatisfaction (ANC: OR 1.53, 95% CI, 1.1–2.1, P=0.015; PPC: OR 
1.88, 95% CI, 1.2–2.9, P=0.004), and living in an urban setting were 
independently associated with any morbidity diagnosis, with urban 
TABLE  1 Characteristics of the antenatal care study population.a,b
Antenatal care (ANC) Total (n=750) Jamaica (n=253) Kenya (n=258) Malawi (n=239) P value
Maternal age, y 26.2 ± 5.9 25.8 ± 6.2 25.1 ± 5.5 27.7 ± 5.6 0.02
<20 91 (12.1) 37 (14.6) 36 (14.0) 18 (7.5)
20–34 591 (78.8) 193 (76.3) 206 (79.4) 192 (80.3)
≥35 68 (9.1) 23 (9.1) 16 (6.20) 29 (12.1)
Marital status <0.001
No partner 218 (29.1) 147 (58.1) 53 (20.5) 18 (7.5)
Has partner 532 (70.9) 106 (41.9) 205 (79.5) 221 (92.5)
Education <0.001
Primary or less 202 (26.9) 15 (5.9) 125 (48.5) 62 (25.9)
Secondary 370 (49.3) 172 (68.0) 100 (38.8) 98 (41.0)
Higher 178 (23.7) 66 (26.1) 33 (12.8) 79 (33.1)
Literacyc <0.001
Cannot read 28 (3.8) 2 (0.8) 10 (3.9) 16 (6.7)
Can read parts of sentence 44 (5.9) 11 (4.4) 31 (12.4) 2 (0.8)
Can read whole sentence 670 (90.3) 240 (94.9) 210 (83.7) 220 (92.4)
Employed 0.158
No 357 (47.6) 114 (45.1) 117 (45.4) 126 (52.7)
Yes 393 (52.4) 139 (54.9) 141 (54.7) 113 (47.3)
Travel time to facility, min <0.001
<15 100 (13.3) 69 (27.3) 17 (7.0) 14 (5.9)
15–30 321 (42.8) 106 (41.9) 144 (55.8) 71 (29.7)
30–60 198 (26.4) 54 (21.3) 70 (27.1) 74 (30.1)
>60 131 (17.5) 24 (9.5) 27 (10.5) 80 (33.5)
Interview site <0.001
Community clinics 112 (14.9) 112 (44.3) 0 (0.0) 0 (0.0)
ANC clinic at hospital 638 (85.1) 141 (55.7) 258 (100.0) 239 (100.0)
Parity 1.3 ± 1.6 1.2 ± 1.6 1.5 ± 1.4 1.3 ± 1.5 0.002
0 271 (36.1) 111 (43.9) 77 (29.8) 83 (34.7)
1 207 (27.6) 68 (26.9) 69 (26.7) 70 (29.3)
2–4 237 (31.6) 58 (22.9) 101 (39.2) 78 (32.6)
≥5 35 (4.7) 16 (6.3) 11 (4.3) 8 (3.4)
aAll P values refer to χ2 results, unless cell values were <5 and Fisher exact or Kruskal- Wallis tests were employed depending on the variable.
bValues are given as mean ± SD or number (percentage) unless otherwise stated.
cExcludes 1 blind woman and 7 for whom the correct language card was missing.
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residence being somewhat protective (PPC only: OR 0.75, 95% CI, 
0.5–1.1, P=0.097).
While time and resources did not permit a rigorous qualitative 
evaluation of the feasibility and challenges associated with adminis-
tering the tools for research purposes, we did discuss the process with 
data collectors at feedback meetings. The relatively low refusal rate 
was an indication that women were willing to participate in the pro-
cess. During discussions with data collectors to determine the feasibil-
ity and challenges of implementing the tool, it became clear that while 
women were open to talking about difficult topics (violence, mental 
health, and sexual satisfaction) that were not generally associated with 
routine care, interviewers (trained health workers) felt unprepared 
to engage in these discussions, or were concerned that there were 
inadequate referral services for women presenting with these issues/
conditions. Interviewers did agree, however, that these were import-
ant issues and need to be considered in future clinical interactions 
with women, especially the issue of depression.
4  | DISCUSSION
The MMWG’s efforts have led to the development of a measure-
ment instrument to describe nonsevere maternal morbidity in a 
manner that highlights the woman’s experience of pregnancy as 
the starting point. Its woman- centered questions have allowed for 
self- reporting15 of factors contributing to morbidity. The instru-
ment is then strengthened by the clinical perspective through diag-
noses by skilled providers. The pilot study aimed to field test this 
TABLE  2 Characteristics of the postpartum care study population.a,b
Postpartum care (PPC) Total (n=740) Jamaica (n=256) Kenya (n=242) Malawi (n=242) P value
Maternal age, y 25.8 ± 6.3 26.1 ± 6.5 24.7 ± 5.7 26.5 ± 6.3 0.272
<20 115 (15.5) 38 (14.8) 43 (17.8) 34 (14.1)
20–34 550 (74.3) 186 (72.7) 182 (75.2) 182 (75.2)
≥35 75 (10.1) 32 (12.5) 17 (7.0) 26 (10.7)
Marital status <0.001
No partner 227 (30.7) 158 (61.7) 43 (17.8) 26 (10.7)
Has partner 513 (69.3) 98 (38.3) 199 (82.2) 216 (89.3)
Education <0.001
Primary or less 214 (28.9) 27 (10.6) 117 (48.4) 70 (28.9)
Secondary 356 (48.8) 135 (52.7) 99 (40.9) 122 (50.4)
Higher 170 (22.3) 94 (36.7) 26 (10.7) 50 (20.7)
Literacyc <0.001
Cannot read 32 (4.3) 5 (2.0) 7 (2.9) 20 (8.3)
Can read parts of sentence 47 (6.4) 10 (3.9) 27 (11.3) 11 (4.1)
Can read whole sentence 658 (89.3) 241 (94.1) 205 (85.8) 212 (87.6)
Employed 0.005
No 328 (51.9) 119 (46.5) 119 (49.2) 146 (60.3)
Yes 356 (48.1) 137 (53.5) 123 (50.8) 96 (36.7)
Travel time to facility, min <0.001
<15 163 (22.0) 119 (46.5) 22 (9.1) 22 (9.1)
15–30 279 (37.7) 92 (35.9) 121 (50.0) 66 (27.3)
30–60 191 (25.8) 28 (10.9) 75 (31.0) 88 (36.4)
>60 107 (14.5) 17 (6.6) 24 (9.9) 66 (27.3)
Interview site <0.001
Community clinics 201 (27.2) 201 (78.5) 0 (0.0) 0 (0.0)
PPC clinic at hospital 539 (72.8) 55 (21.5) 242 (100.0) 242 (100.0)
Parity 2.3 ± 1.5 2.2 ± 1.5 2.5 ± 1.5 2.3 ± 1.4 0.005
1 273 (36.8) 112 (43.8) 67 (27.7) 94 (38.8)
2–4 405 (54.6) 126 (49.2) 153 (63.2) 126 (52.1)
≥5 62 (8.4) 18 (7.0) 22 (9.1) 22 (9.1)
aAll P values refer to χ2 results, unless cell values were <5 and Fisher exact or Kruskal- Wallis tests were employed depending on the variable.
bValues are given as mean ± SD or number (percentage) unless otherwise stated.
aExcludes 3 women who were blind.
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comprehensive instrument, which aims to standardize the meas-
urement of nonsevere morbidity among antenatal and postpartum 
women. The piloted instrument measured morbidity more broadly by 
incorporating a wide range of self- reported factors, beginning with 
symptoms, contributing factors, and ability to carry out daily activi-
ties (functioning). Additionally, based on study results, we described 
the sociodemographic characteristics of participating women, as well 
as estimating both contributory factors and the prevalence of mater-
nal morbidities/conditions, and their relationship. These represent 
areas for further exploration and strategic development.
Of the approximately 210 million pregnancies that occur every 
year, around 303 000 culminate in a maternal death, yet there is no 
consensus on how many women suffer non- life- threatening com-
plications,16,17 probably due to the wide variety of previous defini-
tions.18,19 Additionally, Koblinsky et al.20 have described the reliability 
issues associated with self- reporting versus diagnoses by community 
or skilled care providers (“gold standard”). Our findings depict a sim-
ilar phenomenon, where women’s reported exposures yielded higher 
prevalence rates than those based on clinical assessment alone, such 
as when mental health and exposure to violence were evaluated.
We believe that addressing symptoms and conditions that women 
identify as rendering them less able to function, or causing signifi-
cant discomfort, will be fundamental to addressing nonsevere mater-
nal morbidity. The challenge, in a setting with limited resources, is to 
improve the health and social service system’s capacity to respond to 
the demand for care that identifying and addressing these issues may 
require. As such, the purpose of the instrument needs to be clear for 
users, and its design should allow persons to utilize those components 
that address their needs. The instrument may need to be designed in 
modules that measure separately those clinical problems that health 
systems should be prepared to assist patients to manage, and issues 
for investigation by specifically interested researchers. However, this 
approach might sideline issues women deem important by relegating 
certain issues to lower priority.
The pilot’s findings and the MMWG’s broader scope of self- 
reported conditions have led to a rethinking of the concept of mater-
nal morbidity as a whole. Traditionally, the progression from healthy 
pregnancy to severe maternal morbidity and mortality has been pre-
sented as a linear or iceberg concept, which does not fully capture 
or reflect certain non- life- threatening conditions that could compli-
cate a woman’s life long term. The pilot results support a more cyclical 
(nonlinear) perspective on maternal morbidity, an idea that is further 
expanded in the paper by Filippi et al.21 in this Supplement.
It is interesting to note that medical problems had similar levels 
of prevalence as obstetric ones in ANC women, and accounted for 
the majority of PPC diagnoses in Jamaica and Kenya. This highlights 
changes in demographic and health status, with the surge of pre- 
existing noncommunicable diseases in parallel with the high preva-
lence of obesity and related medical comorbidities. It may also indicate 
that while the general emphasis of ANC has been on obstetric condi-
tions with high case- fatality rates, such as obstetric hemorrhage, this 
approach may fail to address the universal health needs of women. 
Many women experience their first contact with health services when 
they become pregnant, and this opportunity should be exploited to 
improve their overall health.
Validation exercises are needed to determine the efficacy of the 
instrument in accurately identifying the burden of disease in other set-
tings and populations. Defining hypertension in pregnancy broadly, a 
TABLE  3 Women’s social risk factors in the antenatal care and postpartum care study populations.a,b
Total Jamaica Kenya Malawi P value
Antenatal care (n=750) (n=253) (n=258) (n=239)
Substance usec 0.004
No 720 (96.0) 236 (93.3) 253 (98.1) 231 (96.7)
Yes 30 (4.0) 17 (6.7) 5 (1.9) 8 (3.4)
Exposure to violenced 0.018
No 652 (86.9) 222 (87.8) 211 (82.4) 219 (91.6)
Yes 96 (12.8) 31 (12.3) 45 (17.4) 20 (8.4)
Postpartum care (n=740) (n=256) (n=242) (n=242)
Substance usec <0.001
No 717 (96.9) 236 (92.2) 242 (100.0) 239 (98.8)
Yes 22 (3.0) 20 (7.8) 0 (0.0) 2 (0.8)
Exposure to violenced <0.001
No 655 (88.5) 232 (90.6) 225 (93.0) 198 (82.9)
Yes 81 (11.0) 24 (9.4) 40 (16.5) 17 (7.0)
aAll P values refer to χ2 results, unless cell values were <5 and Fisher exact or Kruskal- Wallis tests were employed depending on the variable.
bValues are given as number (percentage) unless otherwise indicated.
cDefined as use of the following substances: tobacco products, alcoholic beverages, marijuana (ganja), inhalants.
dWomen who responded no or never to the following questions: (1) Are you afraid of your current/most recent husband or partner or anyone else? Would 
you say never, sometimes, many times, most/all of the time?; (2) Since pregnancy/delivery, was there ever a time when you were pushed, slapped, hit, 
kicked, or beaten by (any of) your husband/partner(s) or anyone else?
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TABLE  4 Prevalence of obesity, number, and leading conditions identified during antenatal and postpartum care visits, by country.a,b
Total Jamaica Kenya Malawi P value
Antenatal care (n=750) (n=253) (n=258) (n=239)
Obesity
Body mass Index ≥30 258 (34.9) 114 (45.4) 53 (21.0) 91 (38.4) <0.001
Number of conditions diagnosed 0.018
0 462 (61.6) 139 (54.9) 167 (64.7) 156 (65.3)
1 205 (27.3) 69 (27.3) 73 (28.3) 63 (26.4)
2 65 (8.7) 38 (15.0) 14 (5.4) 13 (5.4)
3–6 18 (2.4) 7 (2.7) 4 (1.6) 7 (2.9)
Categories of conditions
Direct 137 (18.3) 31 (12.3) 42 (16.3) 64 (26.8) <0.001
Indirect 135 (18.0) 62 (24.5) 49 (19.0) 24 (10.4) <0.001
Exposure to violence 96 (12.8) 31 (12.3) 45 (17.4) 20 (8.4) 0.004
Leading direct conditions
Pregnancy infections 78 (10.4) 6 (2.4) 27 (10.5) 45 (18.8) <0.001
Hypertensive disorders 22 (2.9) 9 (3.6) 1 (0.4) 12 (5.0) 0.002
Fetus growth/length anomaly 12 (1.6) 6 (2.4) 3 (1.2) 3 (1.3) 0.581
Other 7 (0.9) 4 (1.6) 0 (–) 3 (1.3) 0.105
Obstetric trauma 5 (0.7) 3 (1.2) 1 (0.4) 1 (0.4) 0.541
Leading indirect conditions
Sexually transmitted infection, vaginitis 51 (6.8) 20 (7.9) 17 (6.6) 14 (5.9) 0.657
Psychiatric 48 (6.4) 40 (15.8) 6 (2.3) 2 (0.8) <0.001
Hematologic 28 (3.7) 10 (4.0) 12 (4.7) 6 (2.5) 0.442
Malaria 9 (1.2) 0 (–) 9 (3.5) 0 (–) <0.001
Respiratory 6 (0.8) 0 (–) 5 (1.9) 1 (0.4) 0.043
Postpartum care (n=740) (n=256) (n=242) (n=242)
Obesity
Body Mass Index ≥30 164 (22.6) 94 (37.3) 32 (13.5) 38 (16.1) <0.001
Number of conditions diagnosed 0.027
0 585 (79.1) 184 (71.9) 195 (80.6) 206 (85.1)
1 112 (15.1) 51 (19.9) 31 (12.8) 30 (12.4)
2 32 (4.3) 15 (5.7) 11 (4.6) 6 (2.5)
3–4 11 (1.4) 6 (2.4) 5 (1.1) 0 (–)
Categories of conditions
Direct 64 (8.7) 19 (7.4) 15 (6.2) 30 (12.4) 0.036
Indirect 94 (12.7) 51 (19.9) 36 (14.9) 7 (2.9) <0.001
Exposure to violence 81 (11.0) 24 (9.4) 40 (16.5) 17 (7.0) <0.001
Leading direct conditions
Hypertensive disorders 30 (4.1) 12 (4.7) 4 (1.7) 14 (5.8) 0.43
Pregnancy infections 28 (3.8) 4 (1.6) 9 (3.7) 15 (6.2) 0.024
Obstetric hemorrhage 2 (0.3) 1 (0.4) 0 (–) 1 (0.4) 0.999
Wound complication 2 (0.3) 1 (0.4) 0 (–) 1 (0.4) 0.999
Other 1 (0.1) 1 (0.4) 0 (–) 0 (–) 0.999
Leading indirect conditions
Sexually transmitted infection, vaginitis 48 (6.5) 38 (14.8) 6 (2.5) 4 (1.7) <0.001
Psychiatric 16 (2.2) 13 (5.1) 2 (0.8) 1 (0.4) <0.001
Hematological 13 (1.8) 3 (1.2) 9 (3.7) 1 (0.4) 0.024
Gastrointestinal 5 (0.7) 1 (0.4) 4 (1.7) 0 (–) 0.088
Other infection 4 (0.5) 2 (0.8) 2 (0.8) 0 (–) 0.554
aAll P values refer to χ2 results, unless cell values were <5 and Fisher exact or Kruskal- Wallis tests were employed depending on the variable.
bValues are given as number (percentage) unless otherwise indicated.
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Ghanaian study documented an 11.3% prevalence of the hypertensive 
disorders of pregnancy22—a much higher rate than this study. It is not 
clear what the possible influence is in case ascertainment of resource 
constraints such as access to equipment, supplies, and diagnostic skills.
Research has shown that the prevalence of physical violence varies 
significantly by setting. Rates are generally higher (15%–71%), however, 
than those found in our study.14 This may be due to the tool having only 
two screening questions, and to their broad scope. When women are 
asked specific questions about their experience with violence, rather 
than more general questions (i.e. “are you afraid…?”), they are more 
likely to respond affirmatively. Yet it is relevant to address exposure to 
violence, especially intimate partner violence, as it has been linked to 
poor ANC utilization,23 low birth weight, and preterm delivery,24 and 
possibly pregnancy- associated suicide and homicide.25
TABLE  5 Health status reported by women attending antenatal and postpartum care visits.a,b
Total Jamaica Kenya Malawi P value
Antenatal care (n=750) (n=253) (n=258) (n=239)
Overall health rating 0.005
Very good 165 (22.0) 72 (28.5) 23 (8.9) 70 (29.3)
Good 411 (54.8) 131 (51.8) 177 (68.6) 103 (43.1)
Neither poor nor good 136 (18.1) 37 (14.6) 52 (20.2) 47 (19.7)
Poor 36 (4.8) 12 (4.7) 6 (2.3) 18 (7.5)
Very poor 2 (0.3) 1 (0.4) 0 (0.0) 1 (0.4)
Have you been told you have anything wrong/any medical condition(s)? 0.034
No 641 (85.5) 213 (84.2) 232 (89.9) 196 (82.1)
Yes 109 (14.5) 40 (15.8) 26 (10.1) 43 (18.0)
Are you taking any medication(s) today? 0.036
No 181 (24.1) 67 (26.5) 48 (18.6) 66 (27.6)
Yes 569 (75.9) 186 (73.5) 210 (81.4) 173 (72.4)
Do you have any other medical conditions or other problem(s) you  
would like to report?
0.611
No 650 (86.7) 215 (85.0) 225 (87.2) 210 (87.8)
Yes 100 (13.3) 38 (15.0) 33 (12.8) 29 (12.1)
Anxiety score 2.6 ± 3.1 3.6 ± 3.8 2.1 ± 2.5 1.6 ± 2.0 <0.001
Depression score 2.4 ± 3.3 4.0 ± 4.3 2.0 ± 2.3 1.1 ± 1.9 <0.001
Postpartum care (n=740) (n=256) (n=242) (n=242)
Overall health ratingc 0.001
Very good 240 (32.4) 102 (39.8) 34 (14.1) 104 (43.0)
Good 418 (56.5) 131 (51.2) 177 (73.1) 110 (45.5)
Neither poor nor good 66 (8.9) 17 (6.6) 27 (11.2) 22 (9.1)
Poor 16 (2.2) 6 (2.3) 4 (1.7) 6 (2.5)
Have you been told you have anything wrong/any medical condition(s)? 0.098
No 695 (93.9) 234 (91.4) 229 (94.6) 232 (95.9)
Yes 45 (6.1) 22 (8.6) 13 (5.4) 10 (4.1)
Are you taking any medication(s) today? <0.001
No 520 (70.3) 150 (58.6) 159 (65.7) 211 (87.2)
Yes 220 (29.7) 106 (41.4) 83 (34.3) 31 (12.8)
Do you have any other medical conditions or other problem(s) you  
would like to report?
0.012
No 673 (91.0) 227 (88.7) 215 (88.8) 231 (95.5)
Yes 67 (9.1) 29 (11.3) 27 (11.2) 11 (4.6)
Anxiety score 1.52 ± 2.4 2.3 ± 2.9 1.5 ± 2.3 0.6 ± 1.5 <0.001
Depression score 1.2 ± 2.0 2.1 ± 2.7 1.0 ± 1.6 0.3 ± 0.9 <0.0001
aAll P values refer to χ2 results, unless cell values were <5 and Fisher exact or Kruskal- Wallis tests were employed depending on the variable.
bValues are given as number (percentage) or mean ± SD unless otherwise indicated.
cNo PPC women reported very poor overall health.
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Similarly, our clinical examination, and self- reporting of depression 
and anxiety (using GAD- 7 and PHQ- 9 for screening), documented a 
low prevalence. In many settings, mental health concerns are highly 
stigmatized. Cases may be missed as patients may somaticize these 
concerns through vague symptoms such as fatigue.26 A Ghanaian 
study utilizing the PHQ in a postnatal population found a rate (3.5%; 
95% CI, 3.2–3.7) that mirrored the one in our Jamaican population 
(3.5%; 95% CI, 1.3–5.8).27 Many social and economic factors have 
been linked to antenatal and postnatal depression, including experi-
encing a first pregnancy,28 being unmarried,29 exposure to intimate 
partner violence,30 and lack of partner/baby father support,31 or of 
family cohesion.28 Identifying and treating these mothers is critical not 
only to their health but also to the survival and development of their 
infants.32 The documented rates require refocusing ANC and PPC ser-
vices to ensure that these women receive appropriate care.
Limitations of the pilot study included a nonrepresentative sam-
ple population, especially in Kenya and Malawi, which was drawn 
from large urban hospitals. Given this relatively healthy population of 
women, we had to aggregate many diagnoses, as numbers were too 
small to separate specific diagnoses. The instrument does not include 
questions addressing the baby’s signs and symptoms, or complica-
tions of labor and delivery, which may also help identify morbidity in 
mothers. Additionally, we were unable to follow the same women over 
time to measure the temporality of conditions, or distinguish between 
conditions that developed during pregnancy and prior to pregnancy 
(i.e. women diagnosed with diabetes mellitus were aggregated into 
the gestational diabetes mellitus category, as most are first tested and 
diagnosed during pregnancy). While the current instrument’s focus 
on women’s health- related functioning is important, it lacks a well- 
being component to illuminate how women interpret the experience 
of pregnancy, and how they feel about their health.
The pilot study presents a novel approach to measuring nonsevere 
maternal morbidity, and furthers the work of WHO and the MMWG to 
standardize the definition, identification, and measurement process. This 
holistic approach to assessing maternal morbidity will provide a basis for 
advocacy for women’s health and rights in the broader context.33
Further research is needed to validate the instrument, and to 
ensure that the data collected can be used to assess and improve 
maternal care, especially postpartum visits and continuing health care 
for women. This is consistent with the EPMM strategy to “address 
all causes of maternal mortality, reproductive and maternal morbidi-
ties and related disabilities”2 and aligns with the progress needed to 
achieve the targets envisioned by the Global Strategy for Women’s, 
Children’s and Adolescents’ Health 2016–203034 and the SDG agenda.
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